Cargando…

Allergen inhalation challenge, refractoriness and the effects of ibuprofen

BACKGROUND: Bronchoprovocation challenges use direct or indirect acting stimuli to induce airflow obstruction. Indirect stimuli either non-allergic/non-IgE mediated (e.g. exercise, mannitol) or allergic/IgE mediated (i.e. allergen) trigger mast cells to release bronchoconstricting mediators (e.g. cy...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomani, Shawn, Cockcroft, Donald W., Davis, Beth E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878003/
https://www.ncbi.nlm.nih.gov/pubmed/27222654
http://dx.doi.org/10.1186/s13223-016-0127-z
_version_ 1782433496558469120
author Nomani, Shawn
Cockcroft, Donald W.
Davis, Beth E.
author_facet Nomani, Shawn
Cockcroft, Donald W.
Davis, Beth E.
author_sort Nomani, Shawn
collection PubMed
description BACKGROUND: Bronchoprovocation challenges use direct or indirect acting stimuli to induce airflow obstruction. Indirect stimuli either non-allergic/non-IgE mediated (e.g. exercise, mannitol) or allergic/IgE mediated (i.e. allergen) trigger mast cells to release bronchoconstricting mediators (e.g. cysteinyl leukotrienes, histamine). Performing repeat challenges within a short timeframe (e.g. 3 h) with non-allergic indirect stimuli results in a diminished, refractory response to the second challenge that is inhibited by non-steroidal anti-inflammatory medications. Cross refractoriness occurs between indirect stimuli. It follows that repeat bronchoprovocation with allergen might exhibit refractoriness that might be altered by ibuprofen. We assessed the response to a second allergen challenge performed 24 h after an initial allergen challenge to determine if the response is refractory. If refractoriness developed, the study aimed to determine whether a single dose of ibuprofen would alter the refractory response to the second allergen challenge. In the absence of a refractory response, the study design allowed for the assessment of the effect of ibuprofen on allergen challenge outcomes, including indices of airway inflammation. METHODS: Thirteen mild atopic asthmatics were enrolled in a randomized, double-blind, placebo controlled, cross-over study. Ibuprofen (400 mg) or placebo was administered 1 h prior to the first of two allergen challenges, performed 24 h apart. Blood and sputum eosinophils, airway responsiveness to methacholine and levels of fractional exhaled nitric oxide were assessed before and 7 h after each allergen challenge. All data were log transformed and differences in geometric means were analyzed by paired t-tests. RESULTS: After placebo, early asthmatic responses for the two challenges were not significantly different (p = 0.82). A single 400 mg dose of ibuprofen decreased both the early (p = 0.03; n = 12) and late asthmatic responses (p = 0.03; n = 3). CONCLUSION: Allergen challenges conducted 24 h apart do not exhibit refractoriness. Single dose ibuprofen inhibits early and late asthmatic responses to allergen bronchoprovocation. Ibuprofen should be withheld for at least 24 h prior to investigations utilizing allergen bronchoprovocation. Trial registration clinicaltrials.gov #NCT02327234
format Online
Article
Text
id pubmed-4878003
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48780032016-05-25 Allergen inhalation challenge, refractoriness and the effects of ibuprofen Nomani, Shawn Cockcroft, Donald W. Davis, Beth E. Allergy Asthma Clin Immunol Research BACKGROUND: Bronchoprovocation challenges use direct or indirect acting stimuli to induce airflow obstruction. Indirect stimuli either non-allergic/non-IgE mediated (e.g. exercise, mannitol) or allergic/IgE mediated (i.e. allergen) trigger mast cells to release bronchoconstricting mediators (e.g. cysteinyl leukotrienes, histamine). Performing repeat challenges within a short timeframe (e.g. 3 h) with non-allergic indirect stimuli results in a diminished, refractory response to the second challenge that is inhibited by non-steroidal anti-inflammatory medications. Cross refractoriness occurs between indirect stimuli. It follows that repeat bronchoprovocation with allergen might exhibit refractoriness that might be altered by ibuprofen. We assessed the response to a second allergen challenge performed 24 h after an initial allergen challenge to determine if the response is refractory. If refractoriness developed, the study aimed to determine whether a single dose of ibuprofen would alter the refractory response to the second allergen challenge. In the absence of a refractory response, the study design allowed for the assessment of the effect of ibuprofen on allergen challenge outcomes, including indices of airway inflammation. METHODS: Thirteen mild atopic asthmatics were enrolled in a randomized, double-blind, placebo controlled, cross-over study. Ibuprofen (400 mg) or placebo was administered 1 h prior to the first of two allergen challenges, performed 24 h apart. Blood and sputum eosinophils, airway responsiveness to methacholine and levels of fractional exhaled nitric oxide were assessed before and 7 h after each allergen challenge. All data were log transformed and differences in geometric means were analyzed by paired t-tests. RESULTS: After placebo, early asthmatic responses for the two challenges were not significantly different (p = 0.82). A single 400 mg dose of ibuprofen decreased both the early (p = 0.03; n = 12) and late asthmatic responses (p = 0.03; n = 3). CONCLUSION: Allergen challenges conducted 24 h apart do not exhibit refractoriness. Single dose ibuprofen inhibits early and late asthmatic responses to allergen bronchoprovocation. Ibuprofen should be withheld for at least 24 h prior to investigations utilizing allergen bronchoprovocation. Trial registration clinicaltrials.gov #NCT02327234 BioMed Central 2016-05-24 /pmc/articles/PMC4878003/ /pubmed/27222654 http://dx.doi.org/10.1186/s13223-016-0127-z Text en © Nomani et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Nomani, Shawn
Cockcroft, Donald W.
Davis, Beth E.
Allergen inhalation challenge, refractoriness and the effects of ibuprofen
title Allergen inhalation challenge, refractoriness and the effects of ibuprofen
title_full Allergen inhalation challenge, refractoriness and the effects of ibuprofen
title_fullStr Allergen inhalation challenge, refractoriness and the effects of ibuprofen
title_full_unstemmed Allergen inhalation challenge, refractoriness and the effects of ibuprofen
title_short Allergen inhalation challenge, refractoriness and the effects of ibuprofen
title_sort allergen inhalation challenge, refractoriness and the effects of ibuprofen
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878003/
https://www.ncbi.nlm.nih.gov/pubmed/27222654
http://dx.doi.org/10.1186/s13223-016-0127-z
work_keys_str_mv AT nomanishawn allergeninhalationchallengerefractorinessandtheeffectsofibuprofen
AT cockcroftdonaldw allergeninhalationchallengerefractorinessandtheeffectsofibuprofen
AT davisbethe allergeninhalationchallengerefractorinessandtheeffectsofibuprofen